drugset / Trial / NCT00785577

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

NCT00785577

Phase 2 Completed 273 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.

Timeline

Start
2008-11
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DASOLAMPANEL ETIBUTIL Small molecule 21 mg Oral
Subject DASOLAMPANEL ETIBUTIL Small molecule 49 mg Oral
Subject DASOLAMPANEL ETIBUTIL Small molecule 105 mg Oral
Comparator Pregabalin Small molecule 100 mg Oral

Indications